|Print Page Close Window|
According to the
"The BD Phoenix™ CPO detect test is a completely new type of phenotypic test, and its range of automation and diagnostic capabilities is unmatched by all other currently marketed tests," said
The BD Phoenix™ CPO detect test, currently available in two configurations as part of the BD Phoenix™ automated microbiology system, detects CPOs and depending on configuration, can provide the Ambler classification of the enzyme produced to help inform clinicians in appropriate therapy selection. The test is included on BD Phoenix™ gram-negative panels, allowing hospital labs to offer it as part of routine antibiotic susceptibility testing.
The test streamlines laboratory workflow by routine, concurrent testing of CPO and susceptibility to one panel. Conventional phenotypic methods for CPO detection can take up to 96 hours, whereas the BD Phoenix™ CPO detect test can accurately detect CPOs in under 36 hours.
"The BD Phoenix™ CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management," said
All versions of the BD Phoenix™ CPO detect test will be available beginning in
About the BD Phoenix™ System
The BD Phoenix™ automated microbiology system provides accurate and reliable identification and antibiotic susceptibility testing of microbial organisms. Using BD Phoenix™ products, laboratories can identify organisms and detect emerging antimicrobial resistance, as well as improve communication with clinicians to help impact both patient management and antibiotic stewardship.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-diagnostic-test-helps-hospitals-more-quickly-identify-and-treat-emerging-antibiotic-resistant-bacteria-300748696.html
SOURCE BD (